目的观察紫杉醇联合替吉奥胶囊治疗晚期胃癌的近期疗效和安全性。方法经手术或活检组织病理确诊49例晚期胃癌患者随机分为2组,对照组(24例)给予紫杉醇+亚叶酸钙+氟尿嘧啶方案化疗,观察组(25例)给予紫杉醇联合替吉奥胶囊方案化疗,2组均21d为1个周期;化疗2个周期进行1次疗效评定,以化疗结束时疗效作为最终疗效;观察并比较2组治疗有效率和不良反应。结果观察组完全缓解2例,部分缓解12例,稳定8例,进展3例,总有效率56.0%;对照组完全缓解1例,部分缓解5例,稳定15例,进展3例,总有效率25.0%,2组比较差异有统计学意义(χ2=4.871,P=0.027);观察组和对照组Ⅰ～Ⅱ度恶心呕吐发生率比较差异有统计学意义(χ2=7.351,P=0.007),2组骨髓抑制、贫血、腹泻或便秘、脱发、口腔炎、肝功能损害、肾功能损害发生率比较差异无统计学意义(P>0.05)。结论紫杉醇联合替吉奥胶囊治疗晚期胃癌疗效满意,不良反应轻。 Objective To observe the short-term curative effect and safety of paclitaxel combined with Tebuco capsule in the treatment of advanced gastric cancer. Methods Forty-nine patients with advanced gastric cancer diagnosed by surgery or biopsy were randomly divided into two groups. The control group (24 patients) was treated with paclitaxel plus leucovorin plus fluorouracil chemotherapy. The observation group (25 patients) received paclitaxel plus Chemotherapy, two groups were 21d for a cycle; 2 cycles of chemotherapy for a curative effect evaluation, the curative effect as the final effect of the end of chemotherapy; observe and compare the two groups of treatment efficiency and adverse reactions. Results In the observation group, 2 cases were completely relieved, 12 cases were partially relieved, 8 were stable, 3 were progressive and the total effective rate was 56.0%. In the control group, 1 was completely relieved, 5 were partially relieved, 15 were stable, 3 were progressive. The total effective rate 25.0% in the two groups (χ2 = 4.871, P = 0.027). There was significant difference in the incidence of grade Ⅰ ~ Ⅱ nausea and vomiting between the observation group and the control group (χ2 = 7.351, P = 0.007) The incidence of bone marrow suppression, anemia, diarrhea or constipation, alopecia, stomatitis, impaired liver function and renal dysfunction were not significantly different between the two groups (P> 0.05). Conclusion Paclitaxel combined with Teglitazone capsules is effective in treating advanced gastric cancer with mild adverse reactions.